[10] The first amylin analogue to reach the clinic, pramlintide, demonstrated that the pathway could be drugged, but native-style amylin analogues are short-acting and were used as multiple-daily injections, which limited their appeal for weight management
What we are not talking about enough GLP-1induced weight loss is not just fat loss Emerging concerns: Sarcopenia Up to 2540% of weight loss may be lean mass especially relevant in older adults If patients lose both fat and muscle on treatment, then stop the drug and regain mostly fat, they may not simply return to baseline
This was not altered by treatment with liraglutide for 14 days ( Supplementary Figures S1C, D ) Finally, blood glucose levels were examined in the non-fasted state before and after 10 days of treatment
Preliminary results suggest that the peptide might have played a role in a possible weight increase and a potential rise in the tibial and vertebral bone mineral content as detected by DXA, compared to the control group
Serum IGF-1 levels remained unchanged, confirming the peptide does not activate growth-promoting pathways